JP2000506173A - 眼の光力学的治療による視力の改善 - Google Patents
眼の光力学的治療による視力の改善Info
- Publication number
- JP2000506173A JP2000506173A JP9532132A JP53213297A JP2000506173A JP 2000506173 A JP2000506173 A JP 2000506173A JP 9532132 A JP9532132 A JP 9532132A JP 53213297 A JP53213297 A JP 53213297A JP 2000506173 A JP2000506173 A JP 2000506173A
- Authority
- JP
- Japan
- Prior art keywords
- eye
- patient
- alkyl
- photoactive
- green porphyrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.人の視力を改善する方法で、 a)その処置を必要とする患者に、当該患者の眼中にその有効量が局在化する に足る量の光活性化合物の調合物を投与し、 b)当該光活性化合物の有効量が当該眼中に局在化するに足る時間を経過させ 、 c)当該光活性化合物によって吸収される光を眼に照射する、 ことを特徴とする方法。 2.当該患者の眼が不所望の血管新生を含有する請求項1記載の方法。 3.血管新生が脈絡膜の血管新生である請求項2記載の方法。 4.光活性剤が、グリーンポルフィリン、ヘマトポルフィリン誘導体、クロリン 又はフロリンである請求項1記載の方法。 5.当該光活性化合物がグリーンポルフィリンである請求項4記載の方法。 6.当該グリーンポルフィリンが、図1の式1−3又は1−4の化合物であり、 R1及びR2は、各々独立に、カルボアルコキシル(2−6C)、アルキル(1−6 C)、アリールスルホニル(6−10C)、シアノ及び−CONR5COから成る群 から選択され、R5はアリール(6−10C)又はアルキル(1−6C)であり 、 各々のR3は、独立に、カルボキシル、カルボキシアルキル(2−6C)、又は その塩、アミド、エステル若しくはアシルヒドラゾンであり、又はアルキル(1 −6C)であり、 R4はCH=CH2又は−CH(OR4')CH3であり、R4'はH若しくは親水 性置換基により任意に置換されることのあるアルキル(1−6C)である請求項 5記載の方法。 7.当該グリーンポルフィリンが、図1の図1−3又は1−4で示される式に含 まれ、R1及びR2は、各々独立に、カルボアルコキシル(2−6C)であり、 一つのR3はカルボキシアルキル(2−6C)、他方のR3はカルボキシアルキル( 2−6C)置換基のエステルであり、R4はCH=CH2又は−CH(OH)CH3 である請求項6記載の方法。 8.当該グリーンポルフィリンが、図1−3に示された式に含まれ、式中R1、 及びR2はメトキシカルボニルであり、一つのR3は−CH2CH2COOCH3、 他方のR3はCH2CH2COOHであり、R4はCH=CH2、即ちBPD−MA である請求項7記載の方法。 9.当該調合物が低密度リポたん白質との複合体を形成する当該光活性剤を含む 請求項1記載の方法。 10.当該調合物がリポソーム製剤である請求項1記載の方法。 11.当該患者が年齢関連性斑状変性(AMD)と診断されている請求項1記載 の方法。 12.当該工程a)、b)、及びc)が少なくとも1回繰返される請求項1記載の 方法。 13.当該患者が、斑状の変性、眼のヒストプラズマ症候群、近視及び炎症性疾 患から成る群から選択された1つの状態と診断されている請求項1記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/613,420 | 1996-03-11 | ||
US08/613,420 US5756541A (en) | 1996-03-11 | 1996-03-11 | Vision through photodynamic therapy of the eye |
PCT/CA1997/000134 WO1997033619A1 (en) | 1996-03-11 | 1997-02-25 | Improved vision through photodynamic therapy of the eye |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006064119A Division JP2006273853A (ja) | 1996-03-11 | 2006-03-09 | 眼の光力学的治療による視力改善用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000506173A true JP2000506173A (ja) | 2000-05-23 |
Family
ID=24457246
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9532132A Pending JP2000506173A (ja) | 1996-03-11 | 1997-02-25 | 眼の光力学的治療による視力の改善 |
JP2006064119A Pending JP2006273853A (ja) | 1996-03-11 | 2006-03-09 | 眼の光力学的治療による視力改善用組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006064119A Pending JP2006273853A (ja) | 1996-03-11 | 2006-03-09 | 眼の光力学的治療による視力改善用組成物 |
Country Status (22)
Country | Link |
---|---|
US (6) | US5756541A (ja) |
EP (1) | EP0894009B1 (ja) |
JP (2) | JP2000506173A (ja) |
KR (1) | KR100433507B1 (ja) |
CN (1) | CN1104908C (ja) |
AR (2) | AR004422A1 (ja) |
AT (1) | ATE301473T1 (ja) |
CA (1) | CA2248087C (ja) |
CZ (1) | CZ299301B6 (ja) |
DE (1) | DE69733943T2 (ja) |
DK (1) | DK0894009T3 (ja) |
ES (1) | ES2246505T3 (ja) |
FI (1) | FI981954A (ja) |
HK (1) | HK1018203A1 (ja) |
HU (1) | HU227978B1 (ja) |
IL (4) | IL126099A (ja) |
NO (1) | NO984163L (ja) |
NZ (1) | NZ331736A (ja) |
PL (1) | PL188888B1 (ja) |
TW (1) | TW448045B (ja) |
WO (1) | WO1997033619A1 (ja) |
ZA (1) | ZA971820B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007503436A (ja) * | 2003-08-26 | 2007-02-22 | セラムオプテック インダストリーズ インコーポレーテッド | 光力学治療用の非極性光増感剤 |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005369B1 (en) * | 1996-12-11 | 2003-05-21 | Pharmacyclics, Inc. | Use of a texaphyrin in the preparation of a medicament for use in ocular diagnosis and therapy |
US6270749B1 (en) | 1996-12-11 | 2001-08-07 | Pharmacyclics, Inc. | Use of Texaphyrin in ocular diagnosis and therapy |
JP4012575B2 (ja) * | 1997-02-11 | 2007-11-21 | キューエルティー インコーポレイテッド | 炎症の影響を低減するための組成物および物品 |
US6274614B1 (en) | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
US6117862A (en) | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
US7022843B1 (en) | 1999-04-14 | 2006-04-04 | The University Of British Columbia | β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
US20020022032A1 (en) * | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US7078014B2 (en) * | 1999-12-23 | 2006-07-18 | Health Research, Inc. | Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
US7097826B2 (en) | 1999-12-23 | 2006-08-29 | Health Research, Inc. | Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
US6534040B2 (en) | 1999-12-23 | 2003-03-18 | Health Research, Inc. | Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
EP1267935A2 (en) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
AU2006203034B2 (en) * | 2000-02-10 | 2006-09-07 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
ES2311507T3 (es) | 2000-02-10 | 2009-02-16 | MASSACHUSETTS EYE & EAR INFIRMARY | Terapia fotodinamica para tratamiento de afecciones oftalmicas. |
BR0109499A (pt) * | 2000-03-24 | 2002-12-10 | Novartis Ag | Tratamento melhorado de neovascularização |
AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
PT1357946E (pt) * | 2001-02-06 | 2008-06-27 | Quadra Logic Tech Inc | Terapia fotodinâmica com taxa de fluência reduzida |
US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
US8106038B2 (en) | 2001-02-15 | 2012-01-31 | Qlt Inc. | Method for reducing or preventing PDT related inflammation |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
OA12720A (en) * | 2001-11-09 | 2006-06-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases. |
JP2005527493A (ja) * | 2002-01-23 | 2005-09-15 | ライト サイエンシーズ コーポレイション | 光線力学療法のためのシステムおよび方法 |
KR100896477B1 (ko) * | 2002-03-20 | 2009-05-08 | 노바다크 테크놀러지즈 인코포레이티드 | 관을 통과하는 유체 흐름을 영상화하는 시스템 및 방법 |
WO2004004757A1 (en) * | 2002-07-02 | 2004-01-15 | The Regents Of The University Of California | Treatment for eye disorder |
EP1539067B1 (en) * | 2002-07-17 | 2011-11-30 | Novadaq Technologies Inc. | Combined photocoagulation and photodynamic therapy |
CN1708266A (zh) * | 2002-10-03 | 2005-12-14 | 光科学公司 | 用于眼组织中光反应化合物的激发的系统和方法 |
US20060258629A1 (en) * | 2002-10-18 | 2006-11-16 | Freeman William R | Photodynamic therapy for ocular neovascularization |
WO2004073492A2 (en) * | 2003-02-14 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof |
CA2530166A1 (en) * | 2003-03-07 | 2004-09-23 | Randolph D. Glickman | Antibody-targeted photodynamic therapy |
US20040220167A1 (en) * | 2003-05-02 | 2004-11-04 | Nasrollah Samiy | Methods of treating neuralgic pain |
CN1823038B (zh) * | 2003-05-14 | 2010-05-12 | 索科普哈应用研究产品商业化公司-健康与人类科学Sec | 双亲性三磺酸化四氮杂卟啉在医药中的光动力学应用 |
CN100534428C (zh) * | 2003-08-25 | 2009-09-02 | 上海复旦张江生物医药股份有限公司 | 血卟啉单甲醚在治疗眼科疾病中的应用 |
CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
JP2007536272A (ja) * | 2004-05-07 | 2007-12-13 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 近視の処置法 |
US20060052286A1 (en) * | 2004-08-13 | 2006-03-09 | Yale University | Factor VII conjugates for selectively treating neovascularization disorders |
WO2006021040A2 (en) * | 2004-08-27 | 2006-03-02 | Ellex Medical Pty Ltd | Selective ophthalmic laser treatment |
WO2006036176A1 (en) * | 2004-09-24 | 2006-04-06 | Light Sciences Corporation | Extended treatment of tumors through vessel occlusion with light activated drugs |
US20060189582A1 (en) * | 2004-11-17 | 2006-08-24 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
WO2006065727A1 (en) * | 2004-12-15 | 2006-06-22 | Light Sciences Corporation | Enhanced occlusive effect photodynamic therapy |
WO2006091666A2 (en) * | 2005-02-23 | 2006-08-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US20070122344A1 (en) | 2005-09-02 | 2007-05-31 | University Of Rochester Medical Center Office Of Technology Transfer | Intraoperative determination of nerve location |
JP2009511568A (ja) * | 2005-10-13 | 2009-03-19 | ワラタ ファーマシューティカルズ, インコーポレイテッド | イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用 |
US8658633B2 (en) * | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US20070248646A1 (en) * | 2006-02-16 | 2007-10-25 | Ali Hafezi-Moghadam | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
WO2007129221A2 (en) * | 2006-02-17 | 2007-11-15 | Waratah Parmaceuticals Inc | Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
JP2009529502A (ja) * | 2006-03-09 | 2009-08-20 | ワラタ ファーマシューティカルズ, インコーポレイテッド | タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物 |
WO2007134449A1 (en) * | 2006-05-19 | 2007-11-29 | Waratah Pharmaceuticals Inc. | Screening methods for amyloid beta modulators |
US20080161744A1 (en) | 2006-09-07 | 2008-07-03 | University Of Rochester Medical Center | Pre-And Intra-Operative Localization of Penile Sentinel Nodes |
WO2008034244A1 (en) * | 2006-09-21 | 2008-03-27 | Waratah Pharmaceuticals Inc. | The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases |
US8562595B2 (en) | 2006-10-25 | 2013-10-22 | Ellex R&D Pty Ltd | Retinal regeneration |
US20100292157A1 (en) * | 2006-11-24 | 2010-11-18 | Antonio Cruz | Combination Treatments for Alzheimer's Disease and Similar Diseases |
WO2008103299A2 (en) * | 2007-02-16 | 2008-08-28 | Massachusetts Eye & Ear Infirmary | Methods and compositions for prognosing, detecting, and treating age-related macular degeneration |
US20110105626A1 (en) * | 2007-04-12 | 2011-05-05 | Mclaurin Joanne | Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
CA2683546A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies |
CA2683580A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Treatment of amyotrophic lateral sclerosis |
DK2148667T3 (da) * | 2007-04-12 | 2013-08-26 | Waratah Pharmaceuticals Inc | Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme |
WO2008144828A1 (en) * | 2007-05-30 | 2008-12-04 | Ellex R & D Pty Ltd | Retinal rejuvenation laser |
WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
US8406860B2 (en) | 2008-01-25 | 2013-03-26 | Novadaq Technologies Inc. | Method for evaluating blush in myocardial tissue |
WO2009126894A2 (en) * | 2008-04-11 | 2009-10-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for the diagnosis and treatment of angiogenic disorders |
US10219742B2 (en) | 2008-04-14 | 2019-03-05 | Novadaq Technologies ULC | Locating and analyzing perforator flaps for plastic and reconstructive surgery |
EP3372250B1 (en) | 2008-05-02 | 2019-12-25 | Novadaq Technologies ULC | Methods for production and use of substance-loaded erythrocytes for observation and treatment of microvascular hemodynamics |
JP2012505162A (ja) * | 2008-10-09 | 2012-03-01 | ワラタ ファーマシューティカルズ, インコーポレイテッド | 黄斑変性症関連障害を処置するためのscyllo−イノシトールの使用 |
KR101018785B1 (ko) * | 2008-11-28 | 2011-03-03 | 삼성전기주식회사 | 전자기 밴드갭 구조물 및 회로 기판 |
CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
US10492671B2 (en) | 2009-05-08 | 2019-12-03 | Novadaq Technologies ULC | Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest |
US20140004510A1 (en) | 2010-09-24 | 2014-01-02 | Massachusetts Eye And Ear Infirmary | Methods and compositions for prognosing and/or detecting age-related macular degeneration |
IN2014CN02153A (ja) * | 2011-08-23 | 2015-05-29 | Yeda Res & Dev | |
US9211214B2 (en) | 2012-03-21 | 2015-12-15 | Valeant Pharmaceuticals International, Inc | Photodynamic therapy laser |
US10278585B2 (en) | 2012-06-21 | 2019-05-07 | Novadaq Technologies ULC | Quantification and analysis of angiography and perfusion |
US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
WO2016049756A1 (en) | 2014-09-29 | 2016-04-07 | Novadaq Technologies Inc. | Imaging a target fluorophore in a biological material in the presence of autofluorescence |
KR101955134B1 (ko) | 2014-10-09 | 2019-03-06 | 노바다크 테크놀러지즈 유엘씨 | 형광-조정 광전용적맥파 측정기를 사용한 조직 내의 절대적인 혈류의 정량화 |
CN106620893B (zh) | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
KR102434879B1 (ko) | 2016-05-26 | 2022-08-22 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 폐혈관 질환 치료용 조성물 및 방법 |
CA3049922A1 (en) | 2017-02-10 | 2018-08-16 | Novadaq Technologies ULC | Open-field handheld fluorescence imaging systems and methods |
KR20190056758A (ko) | 2017-11-17 | 2019-05-27 | 주식회사 지뉴브 | 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179120A (en) | 1991-06-28 | 1993-01-12 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
US5776966A (en) | 1992-05-27 | 1998-07-07 | University Of British Columbia | Selective cell inactivation in blood |
CA2185644C (en) * | 1994-03-14 | 2011-04-12 | Joan W. Miller | Use of green porphyrins in ocular diagnosis and therapy |
JP2961074B2 (ja) | 1995-09-06 | 1999-10-12 | 明治製菓株式会社 | 光化学療法用の新生血管閉塞剤 |
-
1996
- 1996-03-11 US US08/613,420 patent/US5756541A/en not_active Expired - Lifetime
-
1997
- 1997-02-25 JP JP9532132A patent/JP2000506173A/ja active Pending
- 1997-02-25 DE DE69733943T patent/DE69733943T2/de not_active Expired - Lifetime
- 1997-02-25 EP EP97903181A patent/EP0894009B1/en not_active Expired - Lifetime
- 1997-02-25 ES ES97903181T patent/ES2246505T3/es not_active Expired - Lifetime
- 1997-02-25 CZ CZ0278998A patent/CZ299301B6/cs not_active IP Right Cessation
- 1997-02-25 WO PCT/CA1997/000134 patent/WO1997033619A1/en active Application Filing
- 1997-02-25 NZ NZ331736A patent/NZ331736A/en not_active IP Right Cessation
- 1997-02-25 AT AT97903181T patent/ATE301473T1/de active
- 1997-02-25 IL IL126099A patent/IL126099A/en not_active IP Right Cessation
- 1997-02-25 HU HU9902012A patent/HU227978B1/hu unknown
- 1997-02-25 KR KR10-1998-0707147A patent/KR100433507B1/ko not_active IP Right Cessation
- 1997-02-25 CA CA002248087A patent/CA2248087C/en not_active Expired - Lifetime
- 1997-02-25 CN CN97192957A patent/CN1104908C/zh not_active Expired - Lifetime
- 1997-02-25 DK DK97903181T patent/DK0894009T3/da active
- 1997-02-25 PL PL97328796A patent/PL188888B1/pl unknown
- 1997-03-03 ZA ZA9701820A patent/ZA971820B/xx unknown
- 1997-03-10 AR ARP970100946A patent/AR004422A1/es not_active Application Discontinuation
- 1997-04-30 TW TW086105744A patent/TW448045B/zh not_active IP Right Cessation
-
1998
- 1998-05-22 US US09/083,480 patent/US5910510A/en not_active Expired - Lifetime
- 1998-09-10 NO NO984163A patent/NO984163L/no not_active Application Discontinuation
- 1998-09-11 FI FI981954A patent/FI981954A/fi unknown
-
1999
- 1999-04-28 US US09/300,979 patent/US6548542B1/en not_active Expired - Lifetime
- 1999-07-22 HK HK99103160A patent/HK1018203A1/xx unknown
-
2003
- 2003-03-07 US US10/383,820 patent/US20030149012A1/en not_active Abandoned
-
2004
- 2004-01-26 AR ARP040100227A patent/AR042931A2/es not_active Application Discontinuation
-
2006
- 2006-03-09 JP JP2006064119A patent/JP2006273853A/ja active Pending
-
2007
- 2007-09-10 US US11/852,965 patent/US8239978B2/en not_active Expired - Fee Related
- 2007-11-29 IL IL187758A patent/IL187758A0/en not_active IP Right Cessation
-
2012
- 2012-06-04 IL IL220143A patent/IL220143A0/en unknown
- 2012-06-06 IL IL220210A patent/IL220210A0/en unknown
- 2012-08-13 US US13/584,617 patent/US20120310144A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007503436A (ja) * | 2003-08-26 | 2007-02-22 | セラムオプテック インダストリーズ インコーポレーテッド | 光力学治療用の非極性光増感剤 |
JP2011213731A (ja) * | 2003-08-26 | 2011-10-27 | Ceramoptec Industries Inc | 光力学治療用の非極性光増感剤 |
JP4869929B2 (ja) * | 2003-08-26 | 2012-02-08 | セラムオプテック インダストリーズ インコーポレーテッド | 光力学治療用の非極性光増感剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000506173A (ja) | 眼の光力学的治療による視力の改善 | |
US6610679B2 (en) | Use of green porphyrins to treat neovasculature in the eye | |
EP0660712B1 (en) | Transcutaneous in vivo activation of photosensitive agents in blood | |
JPH0971531A (ja) | 光化学療法用の新生血管閉塞剤 | |
Kim et al. | Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness | |
US20040220167A1 (en) | Methods of treating neuralgic pain | |
JP2012092145A (ja) | 眼の光力学的治療による視力改善用組成物 | |
AU705100C (en) | Improved vision through photodynamic therapy of the eye | |
Levy et al. | Use Of Green Porphyrinsto Treat Neovasculature In The Eyes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041102 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050202 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050322 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050322 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050920 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051108 |